



05/2023

Products: Paracetamol Baxter 10 mg/ml solution for infusion**Communication on the risk of medication error, leading to an accidental overdose, and the educational materials Baxter will provide to minimize this risk.**

Dear Healthcare Professional,

We would like to take this opportunity to inform you of educational materials that have been approved by the Norwegian Medicines Agency as part of the requirements for the safe use of Paracetamol Baxter 10 mg/ml solution for infusion.

A risk of medication error has been identified that can result in accidental overdose with Paracetamol Baxter 10 mg/ml solution for infusion. This is due to confusion between the units of measurement **ml and mg** in:

- neonates and infants
- underweight adult patients.

In order to reduce this risk, educational materials for Paracetamol Baxter 10 mg/ml solution for infusion have been created. These materials include:

1. Dosing tool for calculating weight-based dosages
2. Poster addressing administration protocol in neonates, infants and children weighing 10 kg or less

This letter is intended for healthcare professionals that may prescribe or be involved in the dispensing and administration of Paracetamol Baxter 10 mg/ml solution for infusion and must be distributed to them at concerned clinics.

Please assist us with communicating this important safety information and instruction material to healthcare professionals that may prescribe or be involved in the dispensing and administration of Paracetamol Baxter by providing the dosing tool and poster to them.

We provide you with the tools described above, with the first shipment of Paracetamol Baxter 10 mg/ml solution for infusion. If more dosing cards or posters are needed, please contact Baxter at kundeservice_NO@baxter.com or tel. 800 33 313 to arrange for shipment of additional specified quantities.

Latest versions of the SmPC and Package Leaflet can be accessed online at:

<https://www.legemiddelsok.no/>

Call for reporting:

Any suspected adverse reactions (ARs) should be reported using the form at the Norwegian Medicines Agency website: www.legemiddelverket.no/pasientmelding



Company Contact Point for AR reporting:

Reports of suspected adverse reactions can also be sent directly to the company via:
vigilanceuk@baxter.com or by filling a form at Baxter website www.baxter.no.

Yours faithfully,

Baxter AS